重症下肢虚血（CLI）治療の世界市場-2025～2032年

世界の重症下肢虚血（CLI）治療市場は、2024年に60億2,000万米ドルに達し、2032年には131億3,000万米ドルに達すると予測され、予測期間2025年のCAGRは7.9％で成長します。

重症下肢虚血（CLI）は、動脈の著しい閉塞を特徴とする重篤な病態であり、四肢、特に脚部への血流が著しく低下します。重症下肢虚血（CLI）は末梢動脈疾患（PAD）の進行期であり、プラークとして知られる脂肪沈着物の蓄積により動脈が徐々に硬化して狭くなるアテローム性動脈硬化症が主な原因です。

重症下肢虚血（CLI）は、安静にしていても足や足の指に強い痛みを感じる慢性疾患です。この痛みはしばしば虚血性安静時痛と呼ばれ、日常生活に深刻な影響を及ぼします。重症下肢虚血（CLI）に伴う合併症には、治癒に必要な血液循環が不十分なために生じる四肢の治癒しない潰瘍や創傷などがあります。これらの合併症を放置すると、患肢の切断を含む重篤な転帰をたどる可能性があります。重症下肢虚血（CLI）は重大な健康リスクをもたらすため、さらなる悪化を防ぎ、四肢の機能を維持するためには、迅速な診断と介入が必要です。これらの要因が、世界の重症下肢虚血（CLI）治療市場拡大の原動力となっています。

市場力学：

促進要因と抑制要因

重症下肢虚血（CLI）の有病率の増加

重症下肢虚血（CLI）の有病率の増加は、世界の重症下肢虚血（CLI）治療市場の成長を大きく牽引しており、市場予測期間を通じて牽引していくと予測されています。

重症下肢虚血（CLI）は、末梢動脈疾患（PAD）の最も重篤な形態として認識されており、下肢の著しい動脈閉塞を特徴とします。この状態は血流を著しく低下させ、潰瘍、壊疽、下肢切断のリスク増加などの重篤な合併症を引き起こします。

末梢動脈疾患（PAD）は一般的な慢性循環疾患であり、血管の狭窄を引き起こし、四肢、特に下肢への血流低下をもたらします。PADはしばしば診断されず、治療も不十分なままであり、推定2,000万人のアメリカ人がPADを患っていますが、正式な診断を受けているのはわずか850万人です。PADは通常、無症状で始まりますが、切断を防ぐために血行再建術が必要となるような重篤な症状に進行することもあります。PADは米国における切断の主な原因であり、致死的および非致死的心血管系イベントの高率と関連しています。

重症下肢虚血（CLI）とは、四肢の重度の虚血状態であり、しばしば虚血性安静時痛、治癒しない潰瘍、または壊疽を伴い、2週間以上持続するものと定義されます。これはPADの最終段階であり、血流が決定的に悪くなり、重大な罹患率につながります。世界中で約2,500万人がCLIに罹患しています。その有病率にもかかわらず、有効な治療法は依然として限られており、これらの患者に対する治療選択肢に大きな隔たりがあることを浮き彫りにしています。

CLIは極めて高い死亡率を伴います。5年間の死亡率は67％にも達し、約20％の患者は診断から6ヵ月以内に死亡します。この高い死亡率は、冠動脈疾患（CAD）や脳血管疾患（CVD）を含む全身性の心血管系疾患の基礎疾患と関連していることが多くあります。CLI患者の予後は、約40％から50％が診断後6ヵ月から12ヵ月以内に脚を失います。さらに、約15％は2年以内に対側切断（もう一方の脚の切断）を余儀なくされます。これらの統計は、効果的な管理戦略の緊急の必要性を強調しています。

さらに、業界の主要企業は臨床試験や製品の上市・承認に力を入れており、これが重症下肢虚血（CLI）治療市場の成長を後押ししています。例えば、2022年3月、LimFlowは、包括的高度慢性下肢虚血（CLTI）を患う患者の切断を予防することを目的とした新規デバイスに焦点を当てたPROMISE II主要試験の患者登録を完了しました。この試験は、他の治療法をすべて使い果たし、四肢切断のリスクが高い患者を対象としており、特に重要です。

また、2022年6月、Koninklijke Philips N.V.は、米国食品医薬品局（FDA）が同社の革新的なデバイスであるPhilips血管内システム-タック（4F）を承認したと発表しました。このデバイスは、四肢の切断を含む重大な罹患率につながる重篤な末梢動脈疾患である重症下肢虚血（CLI）に対処するために特別に設計されています。これらすべての要因が、世界の重症下肢虚血（CLI）治療市場に需要をもたらしています。

さらに、治療オプションの進歩による需要の高まりが、世界の重症下肢虚血（CLI）治療市場の拡大に寄与しています。

高い治療費

高い治療費が重症下肢虚血（CLI）治療の世界市場の成長を抑制します。高度な外科手術や薬物療法を含む重症下肢虚血（CLI）の治療に関連する費用は著しく高額であり、患者とヘルスケアシステムの双方にとって大きな経済的負担につながります。この経済的負担は、特にヘルスケア予算が制約されている発展途上地域において、必要な治療へのアクセスを著しく制限する可能性があります。

CLIの治療には多くの場合、血行再建術（血管形成術、ステント留置術、バイパス手術）や継続的な内科的管理（抗血小板療法、脂質低下剤）などの複雑な介入が必要です。これらの処置は、特殊な機器、熟練した医療専門家、長期入院が必要なため、高額になることがあります。

重症下肢虚血（CLI）と診断されるまでの12ヵ月間にかかった平均費用は、最終的に血管内血行再建術を受けた患者で2万7,500米ドル、外科的血行再建術を受けた患者で2万6,100米ドル、大断端術を必要とした患者で3万8,300米ドルでした。このように、上記の要因が世界の重症下肢虚血（CLI）治療市場の潜在的成長を制限している可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 重症下肢虚血（CLI）の罹患率の増加
  • 抑制要因
    • 高額な治療費
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 特許分析
• 規制分析
• SWOT分析
• アンメットニーズ

第6章 治療の種類別

• 薬物クラス
  • 抗血小板薬
    • アスピリン
    • クロピドグレル
    • チクロピジン
    • ジピリダモール
  • 脂質低下剤
    • アトルバスタチン
    • シンバスタチン
  • 血管拡張薬
    • イロプロスト
    • ナフチドロフリル
  • ホスホジエステラーゼ阻害剤（シロスタゾール）
  • その他
  • 装置
    • 塞栓保護装置
    • 末梢拡張システム
    • 血管ステント
    • その他
  • その他

第7章 エンドユーザー別

• 病院と専門クリニック
• 外来手術センター
• その他

第8章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州地域
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• 中東・アフリカ

第9章 競合情勢

• 競合シナリオ
• 市況・シェア分析
• M&A分析

第10章 企業プロファイル

• Medtronic plc
  • 会社概要
  • 製品ポートフォリオ
  • 製品説明
  • 製品の主要業績評価指標（KPI）
  • 過去および予測の製品販売
  • 製品販売量
  • 財務概要
  • 会社の収益
  • 地域別収益分配
  • 収益予測
  • 主な発展
  • 合併と買収
  • 主な製品開発活動
  • 規制当局の承認等
  • SWOT分析
• Boston Scientific Corporation
• Abbott.（Cardiovascular Systems, Inc.）
• Inari Medical
• Koninklijke Philips N.V.
• Lisata Therapeutics
• Cook
• Baxter
• B. Braun Melsungen AG
• Biotronik SE & Co. KG

第11章 付録

The global critical limb ischemia (CLI) treatment market reached US$ 6.02 billion in 2024 and is expected to reach US$ 13.13 billion by 2032, growing at a CAGR of 7.9 % during the forecast period 2025-2032.

Critical Limb Ischemia (CLI) is a severe condition characterized by significant obstruction of the arteries, leading to markedly reduced blood flow to the extremities, particularly the legs and feet. Critical Limb Ischemia (CLI) represents the advanced stage of Peripheral Artery Disease (PAD), which is primarily caused by atherosclerosis the gradual hardening and narrowing of the arteries due to the accumulation of fatty deposits known as plaque.

Critical limb ischemia (CLI) is a chronic condition that manifests as intense pain in the feet or toes, even when at rest. This pain, often referred to as ischemic rest pain, can severely impact daily life. Complications associated with critical limb ischemia (CLI) include non-healing ulcers and wounds on the extremities, which arise from insufficient blood circulation necessary for healing. If left untreated, these complications can lead to serious outcomes, including amputation of the affected limb. Critical limb ischemia (CLI) poses significant health risks and requires prompt diagnosis and intervention to prevent further deterioration and preserve limb function. These factors have driven the global critical limb ischemia (CLI) treatment market expansion.

Market Dynamics: Drivers & Restraints

Increasing Prevalence of Critical Limb Ischemia (CLI)

The increasing prevalence of critical limb ischemia (CLI) is significantly driving the growth of the global critical limb ischemia (CLI) treatment market and is expected to drive throughout the market forecast period.

Critical limb ischemia (CLI) is recognized as the most severe form of peripheral arterial disease (PAD), characterized by significant arterial blockages in the lower extremities. This condition leads to markedly reduced blood flow, resulting in severe complications such as ulceration, gangrene, and an increased risk of lower-limb amputation.

Peripheral artery disease (PAD) is a common chronic circulatory condition that causes the narrowing of blood vessels, leading to reduced blood flow to the limbs, particularly the legs. It often remains undiagnosed and undertreated, with an estimated 20 million Americans living with PAD, yet only 8.5 million have received a formal diagnosis. While PAD typically begins asymptomatically, it can progress to severe symptoms that may necessitate revascularization procedures to prevent amputation. PAD is the leading cause of amputations in the United States and is associated with high rates of both fatal and non-fatal cardiovascular events.

Critical limb ischemia (CLI) is defined as a state of severe ischemia in the limbs, often accompanied by ischemic rest pain, non-healing ulcers, or gangrene lasting more than two weeks. It represents the end stage of PAD, where blood flow is critically compromised, leading to significant morbidity. Approximately 25 million people worldwide are affected by CLI. Despite its prevalence, effective therapies remain limited, highlighting a significant gap in treatment options for these patients.

CLI is associated with extremely high mortality rates. The five-year mortality rate can be as high as 67%, with about 20% of patients dying within six months of diagnosis. This high mortality is often linked to underlying systemic cardiovascular diseases, including coronary artery disease (CAD) and cerebrovascular disease (CVD). The prognosis for patients with CLI is dire; approximately 40% to 50% will lose their leg within 6 to 12 months after diagnosis. Furthermore, about 15% will require contralateral amputation (amputation of the other leg) within two years. These statistics underscore the urgent need for effective management strategies.

Furthermore, key players in the industry more focus on clinical trials and product launches & approvals that would propel this critical limb ischemia (CLI) treatment market growth. For instance, in March 2022, LimFlow completed patient enrollment for the PROMISE II pivotal trial, which focuses on a novel device aimed at preventing amputations in patients suffering from chronic limb-threatening ischemia (CLTI). This trial is particularly significant as it targets patients who have exhausted all other treatment options and are at high risk of major limb amputation.

Also, in June 2022, Koninklijke Philips N.V. announced that the U.S. Food and Drug Administration (FDA) approved its innovative device, the Philips Endovascular System-Tack (4F). This device is specifically designed to address chronic limb ischemia (CLI), a severe form of peripheral artery disease that can lead to significant morbidity, including limb amputation. All these factors demand the global critical limb ischemia (CLI) treatment market.

Moreover, the rising demand for the growth of advancements in treatment options contributes to the global critical limb ischemia (CLI) treatment market expansion.

High Treatment Costs

The high treatment costs will hinder the growth of the global critical limb ischemia (CLI) treatment market. The costs associated with therapies for critical limb ischemia (CLI), including advanced surgical procedures and medications, are notably high, leading to substantial financial burdens for both patients and healthcare systems. This financial strain can significantly limit access to necessary treatments, especially in developing regions where healthcare budgets are constrained.

CLI treatment often involves complex interventions such as revascularization procedures (angioplasty, stenting, or bypass surgery) and ongoing medical management (antiplatelet therapy, lipid-lowering agents). These procedures can be expensive due to the need for specialized equipment, skilled healthcare professionals, and extended hospital stays.

During the 12 months leading up to the diagnosis of critical limb ischemia (CLI), the average costs incurred were $27,500 for patients who ultimately underwent endovascular revascularization, $26,100 for those treated with surgical revascularization, and $38,300 for patients who required major amputation. Thus, the above factors could be limiting the global critical limb ischemia (CLI) treatment market's potential growth.

Segment Analysis

The global critical limb ischemia (CLI) treatment market is segmented based on Treatment Type, end-user, and region.

Treatment Type:

The vascular stents segment is expected to dominate the global critical limb ischemia (CLI) treatment market share

The vascular stents segment holds a major portion of the global critical limb ischemia (CLI) treatment market share and is expected to continue to hold a significant portion of the global critical limb ischemia (CLI) treatment market share during the forecast period.

Vascular stents are a cornerstone in the treatment of critical limb ischemia, enhancing patient outcomes through effective revascularization strategies. Their development continues to evolve, focusing on improving safety and efficacy in managing this serious condition.

Vascular stents are essential in managing critical limb ischemia (CLI), a severe condition resulting from inadequate blood flow to the limbs, which can lead to pain and tissue loss. The CLI treatment landscape increasingly emphasizes advanced endovascular techniques, particularly the use of stents and balloon angioplasty, which are vital for effective revascularization.

Types of stents include drug-eluting stents (DES) and balloon-expandable stents. Drug-eluting stents (DES): These stents are coated with medication that helps prevent restenosis (the re-narrowing of arteries) by inhibiting cell proliferation. They have demonstrated low rates of repeat revascularization, making them particularly advantageous in CLI management.

Balloon-expandable stents designed to be expanded within the artery using a balloon catheter, these stents allow for precise placement and effective dilation of narrowed vessels. They are commonly used in treating lesions in the infragenicular region, where they have shown safety and efficacy.

The use of vascular stents in CLI has been associated with improved clinical outcomes. For instance, studies indicate that limb salvage rates can reach up to 89.3%, and primary patency rates (the percentage of treated vessels that remain open) can be around 62.8% at one-year post-treatment. The combination of stenting with angioplasty is often superior to angioplasty alone, particularly in cases involving complex lesions.

Furthermore, key players in the industry product launches that would drive this global critical limb ischemia (CLI) treatment market growth. For instance, in November 2023, the LimFlow System (P220025) was a significant medical device recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of Chronic Limb-Threatening Ischemia (CLTI).

This condition is a severe form of peripheral arterial disease (PAD) that leads to critical reductions in blood flow to the lower extremities, often resulting in severe complications such as non-healing wounds and the risk of amputation. These factors have solidified the segment's position in the global critical limb ischemia (CLI) treatment market.

Geographical Analysis

North America is expected to hold a significant position in the global critical limb ischemia (CLI) treatment market share

The incidence of CLI is on the rise, with estimates indicating that between 2 million and 3 million individuals in the U.S. are affected. This growing patient population underscores the necessity for more effective treatment options to manage the condition effectively. CLI often leads to serious health complications, necessitating frequent hospitalizations; in fact, up to 60% of patients may be readmitted within six months of their initial treatment.

Chronic limb-threatening ischemia (CLTI) affects up to four million Americans, with a disproportionate impact on minority and underserved populations. This condition leads to severe arterial blockages in the lower extremities, resulting in inadequate blood flow, which can cause significant complications, including non-healing ulcers and gangrene. Each year, more than 150,000 major amputations are performed in the U.S. due to CLI.

The prevalence of diabetes, a major risk factor for CLI, is expected to continue increasing. Current projections suggest that the number of Americans with diabetes could rise from 32 million to 36 million by 2050, further fueling market growth as more individuals develop conditions leading to CLI. The availability of innovative medical devices, such as drug-eluting stents and minimally invasive surgical options, significantly enhances treatment efficacy and patient outcomes. These advancements are driving demand within the CLI treatment market.

Furthermore, a major number of key players' presence, innovative product launches, and approvals would propel this global critical limb ischemia (CLI) treatment market growth. For instance, in September 2023, LimFlow SA, a pioneer in minimally invasive technology for treating Chronic Limb-Threatening Ischemia (CLTI), announced that the U.S. Food and Drug Administration (FDA) has approved its LimFlow System. This approval is significant as it provides a new treatment option for patients suffering from CLTI who have no other suitable endovascular or surgical interventions available and are at risk of major amputation.

Also, in August 2021, the U.S. Food and Drug Administration (FDA) approved an expanded indication for XARELTO (rivaroxaban) in combination with aspirin, specifically for patients suffering from Peripheral Artery Disease (PAD) who have recently undergone lower-extremity revascularization (LER) due to symptomatic PAD. This approval marks a significant advancement in the management of PAD, particularly for patients at high risk for serious thrombotic events.

Thus, the above factors are consolidating the region's position as a dominant force in the global critical limb ischemia (CLI) treatment market.

Asia Pacific is growing at the fastest pace in the global critical limb ischemia (CLI) treatment market share

Asia Pacific holds the fastest pace in the global critical limb ischemia (CLI) treatment market and is expected to hold most of the market share.

The incidence of CLI is rising notably in countries like India and China, where lifestyle changes and an aging population contribute to higher rates of peripheral artery disease. This expanding patient population necessitates more effective treatment options. The growth of the elderly population across Asia-Pacific countries is a critical driver, as older adults are more susceptible to CLI and related cardiovascular conditions. This demographic shift increases the demand for specialized treatments.

There has been a significant increase in healthcare expenditure in the region, which facilitates better access to advanced medical technologies and treatments for CLI. This financial support enables healthcare systems to adopt innovative therapies and devices. Governments are actively implementing initiatives aimed at raising awareness about CLI and its risk factors, promoting early diagnosis and treatment. Such efforts are crucial for improving patient outcomes and effectively managing the disease.

Furthermore, key players in the industry have innovative launches and approvals that would propel this critical limb ischemia (CLI) treatment market growth. HONEDRA is an innovative experimental regenerative medicine developed as a treatment for Chronic Limb Ischemia (CLI) and Buerger's disease in Japan. It has been designated as a SAKIGAKE product candidate, which is a special designation by the Japanese regulatory authority aimed at expediting the development and review of innovative medical products.

Also, Stempeucel is an innovative stem cell-based biological product that has received approval from the Drug Controller General of India (DCGI), marking it as the first of its kind to be approved for manufacturing and marketing for the treatment of Critical Limb Ischemia (CLI). This approval represents a significant advancement in the therapeutic options available for patients suffering from this severe condition.

Thus, the above factors are consolidating the region's position as the fastest-growing force in the global critical limb ischemia (CLI) treatment market.

Competitive Landscape

The major global players in the critical limb ischemia (CLI) treatment market include Medtronic plc, Boston Scientific Corporation, Abbott. (Cardiovascular Systems, Inc.), Inari Medical, Koninklijke Philips N.V., Lisata Therapeutics, Cook, Baxter, B. Braun Melsungen AG, and Biotronik SE & Co. KG among others.

Key Developments

• In April 2024, the FDA's recent approval of Abbott's Espirit BTK Everolimus Eluting Resorbable Scaffold System marks a significant advancement in the treatment of Chronic Limb-Threatening Ischemia (CLTI), particularly in arteries below the knee. This innovative treatment represents the first dissolving stent approved in the United States specifically for this condition.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global critical limb ischemia (CLI) treatment market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals & Specialty Clinics.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Treatment Type
• 3.2. Snippet by End-User
• 3.3. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing Prevalence of Critical Limb Ischemia (CLI)
  • 4.1.2. Restraints
    • 4.1.2.1. High Treatment Costs
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Patent Analysis
• 5.5. Regulatory Analysis
• 5.6. SWOT Analysis
• 5.7. Unmet Needs

6. By Treatment Type

• 6.1. Introduction
  • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 6.1.2. Market Attractiveness Index, By Treatment Type
• 6.2. Drug Class*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.2.3. Antiplatelet Drugs
    • 6.2.3.1. Aspirin
    • 6.2.3.2. Clopidogrel
    • 6.2.3.3. Ticlopidine
    • 6.2.3.4. Dipyridamole
  • 6.2.4. Lipid-lowering Agents
    • 6.2.4.1. Atorvastatin
    • 6.2.4.2. Simvastatin
  • 6.2.5. Vasodilators
    • 6.2.5.1. Iloprost
    • 6.2.5.2. Naftidrofuryl
  • 6.2.6. Phosphodiesterase Inhibitor (Cilostazol)
  • 6.2.7. Others
  • 6.2.8. Devices
    • 6.2.8.1. Embolic Protection Devices
    • 6.2.8.2. Peripheral Dilatation Systems
    • 6.2.8.3. Vascular Stents
    • 6.2.8.4. Others
  • 6.2.9. Others

7. By End-User

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 7.1.2. Market Attractiveness Index, By End-User
• 7.2. Hospitals & Specialty Clinics *
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Ambulatory Surgical Centers
• 7.4. Others

8. By Region

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 8.1.2. Market Attractiveness Index, By Region
• 8.2. North America
  • 8.2.1. Introduction
  • 8.2.2. Key Region-Specific Dynamics
  • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.2.5.1. U.S.
    • 8.2.5.2. Canada
    • 8.2.5.3. Mexico
• 8.3. Europe
  • 8.3.1. Introduction
  • 8.3.2. Key Region-Specific Dynamics
  • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.3.5.1. Germany
    • 8.3.5.2. U.K.
    • 8.3.5.3. France
    • 8.3.5.4. Spain
    • 8.3.5.5. Italy
    • 8.3.5.6. Rest of Europe
• 8.4. South America
  • 8.4.1. Introduction
  • 8.4.2. Key Region-Specific Dynamics
  • 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.4.5.1. Brazil
    • 8.4.5.2. Argentina
    • 8.4.5.3. Rest of South America
• 8.5. Asia-Pacific
  • 8.5.1. Introduction
  • 8.5.2. Key Region-Specific Dynamics
  • 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.5.5.1. China
    • 8.5.5.2. India
    • 8.5.5.3. Japan
    • 8.5.5.4. South Korea
    • 8.5.5.5. Rest of Asia-Pacific
• 8.6. Middle East and Africa
  • 8.6.1. Introduction
  • 8.6.2. Key Region-Specific Dynamics
  • 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9. Competitive Landscape

• 9.1. Competitive Scenario
• 9.2. Market Positioning/Share Analysis
• 9.3. Mergers and Acquisitions Analysis

10. Company Profiles

• 10.1. Medtronic plc*
  • 10.1.1. Company Overview
  • 10.1.2. Product Portfolio
  • 10.1.3. Product Description
  • 10.1.4. Product Key Performance Indicators (KPIs)
  • 10.1.5. Historic and Forecasted Product Sales
  • 10.1.6. Product Sales Volume
  • 10.1.7. Financial Overview
  • 10.1.8. Company Revenue's
  • 10.1.9. Geographical Revenue Shares
  • 10.1.10. Revenue Forecasts
  • 10.1.11. Key Developments
  • 10.1.12. Mergers & Acquisitions
  • 10.1.13. Key Product Development Activities
  • 10.1.14. Regulatory Approvals etc.
  • 10.1.15. SWOT Analysis
• 10.2. Boston Scientific Corporation
• 10.3. Abbott. (Cardiovascular Systems, Inc.)
• 10.4. Inari Medical
• 10.5. Koninklijke Philips N.V.
• 10.6. Lisata Therapeutics
• 10.7. Cook
• 10.8. Baxter
• 10.9. B. Braun Melsungen AG
• 10.10. Biotronik SE & Co. KG

LIST NOT EXHAUSTIVE

11. Appendix

• 11.1. About Us and Services
• 11.2. Contact Us